Related references
Note: Only part of the references are listed.Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency
Xiaochuan Dong et al.
GUT (2022)
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
F. Lordick et al.
ANNALS OF ONCOLOGY (2022)
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Leo Yamada et al.
GASTRIC CANCER (2021)
The real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
Kiwamu Akagi et al.
CANCER SCIENCE (2021)
ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Koji Kase et al.
CARCINOGENESIS (2021)
PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms
Hiroshi Nakano et al.
SCIENTIFIC REPORTS (2021)
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
Masahiko Aoki et al.
GASTRIC CANCER (2021)
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
Kohei Shitara et al.
GASTRIC CANCER (2021)
Landscape of EBV-positive gastric cancer
Motonobu Saito et al.
GASTRIC CANCER (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells
Shotaro Nakajima et al.
SCIENTIFIC REPORTS (2021)
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
S. J. Isakoff et al.
ANNALS OF ONCOLOGY (2020)
Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Willemieke P. M. Dijksterhuis et al.
GASTRIC CANCER (2020)
The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion
Aya Shinozaki-Ushiku et al.
GASTRIC CANCER (2020)
Current status of immune checkpoint inhibitors for gastric cancer
Koji Kono et al.
GASTRIC CANCER (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Y-J Bang et al.
EUROPEAN JOURNAL OF CANCER (2019)
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
M. Oliveira et al.
ANNALS OF ONCOLOGY (2019)
Prognostic role of ARID1A negative expression in gastric cancer
Mai Ashizawa et al.
SCIENTIFIC REPORTS (2019)
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion
Mike R. Wilson et al.
NATURE COMMUNICATIONS (2019)
Targeted and novel therapy in advanced gastric cancer
Julie H. Selim et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Asuncion Diaz-Serrano et al.
ONCOLOGIST (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Estimation of lifetime cumulative incidence and mortality risk of gastric cancer
Yukari Taniyama et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells
Dakeun Lee et al.
ONCOTARGETS AND THERAPY (2017)
Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
Melissa A. Jim et al.
CANCER (2017)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Recent advances in the HER2 targeted therapy of gastric cancer
Tasuku Matsuoka et al.
WORLD JOURNAL OF CLINICAL CASES (2015)
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem et al.
GASTRIC CANCER (2015)
Whole Genome Gene Copy Number Profiling of Gastric Cancer Identifies PAK1 and KRAS Gene Amplification as Therapy Targets
Ziliang Qian et al.
GENES CHROMOSOMES & CANCER (2014)
Significance of AKT in gastric cancer (Review)
Takamitsu Sasaki et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
Tasuku Matsuoka et al.
CANCERS (2014)
Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
Kohei Shitara et al.
GASTRIC CANCER (2013)
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
Zhengdeng Lei et al.
GASTROENTEROLOGY (2013)
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
Jing Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
Kai Wang et al.
NATURE GENETICS (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Share Paper
